Top

News & Events

Archive: 2016

News Archive

Licence agreement for Composite Human Antibody™ technology

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Trieza Therapeutics, Inc (‘Trieza’). Trieza is a start-up biotechnology company specialising in the discovery and development of immunomodulatory oncolytic viruses based in Cambridge, MA, USA.

Read more »

New Data Shows that MammaPrint® Substantially Impacts how Breast Cancer Patients in Germany are Treated

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, has presented new prospective data1 demonstrating the strong impact of its 70-Gene Breast Cancer Recurrence assay, MammaPrint®, and the corresponding 80-Gene Molecular Subtyping Assay BluePrint®, in clinical decision-making for patients with early-stage breast cancer in Germany.

Read more »

Portfolio company PsiOxus Therapeutics signs exclusive worldwide licence agreement with BMS for NG-348 its first “armed” oncolytic virus

Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) is pleased to note that portfolio company PsiOxus Therapeutics (‘PsiOxus’ or the ‘Company’) has announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus which may serve as a novel mechanism to address solid tumours.

Read more »

Recce reports encouraging anti-viral activity for lead compound RECCE® 327

SYDNEY Australia:  Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics to treat serious infections, today announced encouraging early results for the company's lead product candidate RECCE® 327 as a potential anti-viral agent.

Read more »

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today reported final results from its Phase 1 trial of AB-SA01, a proprietary investigational bacteriophage (phage) cocktail targeting Staphylococcus aureus (S. aureus) infections, in patients with chronic rhinosinusitis (CRS).  AB-SA01 met the trial’s primary endpoints of safety and tolerability and all nine patients enrolled in the study experienced a reduction in the quantity of S. aureus infecting their sinuses, with some patients showing complete eradication of the bacterial infection.

Read more »

Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint® and BluePrint® in Individualizing Treatment for Breast Cancer Patients

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, highlights new data on its gold-standard MammaPrint 70-Gene Breast Cancer Recurrence Assay and BluePrint 80-Gene Molecular Subtyping Assay, from three studies presented at the San Antonio Breast Cancer Symposium last week.

Read more »

Clinigen signs Global Access agreement for BioQ Pharma’s post-operative pain management product, Ropivacaine Readyfusor

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that its Idis Global Access (GA) division has signed a supply and distribution agreement with BioQ Pharma, a developer of large volume ready-to-use infusible products. The deal covers the on-demand supply and distribution of BioQ Pharma’s pre-filled Ropivacaine Readyfusor for post-operative pain management in Europe, excluding France and Germany.

Read more »

Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial

Paris, France and Cambridge, Massachusetts, USA – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces a positive readout of initial data on the safety and feasibility from the first patients treated in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and metastatic tumors.

Read more »

Dimerix Receptor-HIT data presented by Takeda at British Pharmacological Society Annual meeting

Melbourne, Australia - Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced that Dr Louise Dickson from Takeda Pharmaceutical Company Limited (Takeda: www.takeda.com) has presented work conducted using the Dimerix Receptor-HIT technology to help define new G Protein-Coupled Receptor (GPCR) functions, which could lead to novel therapies.

Read more »

Higher M&A Activity and Investor Cash Expected to Re-invigorate Pharma and Biotech in 2017

Annual “EP Vantage 2017 Preview” report discusses what’s in store for biopharma in the coming year

LONDON, BOSTON, SAN FRANCISCO, TOKYO – Despite the uncertainty that loomed over the pharma and biotech sectors with unexpected outcomes from both the US presidential election and UK’s vote to leave the EU, 2017 may bring renewed energy to the industry with potential for more corporate activity and cash flow.

Read more »

Adherium’s Smartinhaler™ technology chosen for major asthma initiative

Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announces that some of Europe’s most prestigious clinical opinion leaders have chosen Adherium’s Smartinhaler™ for the myAirCoach programme, part of the European Union’s Horizon 2020 Framework for Research and Innovation. The myAirCoach programme is being funded through the Horizon 2020 framework which is the largest EU Research and Innovation programme ever established with nearly €80 billion of funding available over 7 years (2014 to 2020).

Read more »

Polyganics announces Birmingham Hand Centre efficacy study of nerve conduit NEUROLAC® in finger surgery

Groningen, The Netherlands, 7 Dec 2016 – Polyganics, a privately held medical technology company focused on the development, manufacturing and commercialization of innovative bioresorbable medical devices that facilitate tissue repair and regeneration, announced today the launch of the CONNECT study, in collaboration with the Birmingham Hand Centre, part of the University Hospitals Birmingham NHS Foundation Trust in the UK. The study has been developed to deliver improvements in peripheral nerve repair after injury.

Read more »

OBN BioTuesday: Sources of public non-dilutable funding and export support to UK R&D companies

6 December 2016
OBN BioTuesday: Sources of public non-dilutable funding and export support to UK R&D companies
Gatwick, UK

Read more »

Dimerix Completes Recruitment of Part A of its Phase 2 Trial of DMX-200 in Chronic Kidney Disease

MELBOURNE, Australia - Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced that it has completed recruitment of patients into Part A of its Phase 2 trial for DMX-200, an innovative new treatment chronic kidney disease that combines two different existing drugs.

Read more »

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01

SAN DIEGO, December 5, 2016 – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today reported final results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections.  Overall, treatment with AB-SA01 was well tolerated when administered topically to the intact skin of healthy adults.  The trial was conducted under a Collaborative Research and Development Agreement with the U.S. Army at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland.

Read more »

Puridify and GSK extend evaluation of FibroSelect purification technology

London, UK - 5 December 2016 - Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the signing of an
18 month collaboration with GlaxoSmithKline (“GSK”) to extend the evaluation of Puridify’s FibroSelect purification technology with a view to building a package to support potential use of nanofibres in toxicology and clinical manufacture.  This signing follows a previous 18 month collaboration which has seen successful demonstration of proof of concept studies at the 50L scale, with potential calculated economic benefits based on the technology’s use.

Read more »

Instinctif Partners named Regional Independent Consultancy of the Year (EMEA) at ICCO Awards

The International Communications Consultancy Organisation (ICCO) has awarded the accolade of Regional Independent Consultancy of the Year (EMEA) to Instinctif Partners at an awards ceremony in London on Thursday 1 December 2016.

Read more »

Agendia’s MammaPrint® and BluePrint® Tests Highlighted in Multiple Presentations at the 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility

Agendia will also host two additional educational opportunities for physicians and patient advocates during this year’s conference

Irvine, CA, USA and Amsterdam, the Netherlands -- Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that the MammaPrint® and BluePrint® tests will be highlighted in nine scientific presentations at the upcoming 2016 San Antonio Breast Cancer Symposium (SABCS).

Read more »

DNAe Congratulates Executive Chairman Professor Chris Toumazou on Elektra European Electronics Industry Lifetime Achievement Award

London, UK and Carlsbad, CA – DNA Electronics (‘DNAe’), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology and developers of a revolutionary blood-to-result test for bloodstream infections, congratulates its founder and Executive Chairman Regius Professor Chris Toumazou (FRS, FREng, FIEEE, FIET, FRSM, FCGI, CEng, DEng, PhD) on receipt of the Lifetime Achievement Award which was announced at the 2016 Elektra European Electronics Industry Awards ceremony in London last night.

Read more »

Genesis 2016

1 December 2016
Genesis 2016
London, UK

Read more »

Halaven® (eribulin) receives registration in South Africa for treatment of women with advanced breast cancer

Collaboration between Eisai and Clinigen provides women in South Africa with access to eribulin for advanced breast cancer

Halaven® (eribulin) is now registered by the Medicines Control Council (MCC) in South Africa for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Eribulin was discovered and developed by Eisai and will be available to people in South Africa through a partnership with Equity Pharma, part of Clinigen’s Link Healthcare division.

Read more »

Half year results: Integrated service offering driving revenue growth

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes its half year results for the six months to 30 September 2016.

Read more »

Genesis Fringe - Anti-Microbial Resistance Seminar

30 November 2016
Genesis Fringe - Anti-Microbial Resistance Seminar
London, UK

Read more »

BIA Investor Breakfast - Brexit, Industrial Strategy and Investment in the Life Sciences Sector

29 November 2016
BIA Investor Breakfast - Brexit, Industrial Strategy and Investment in the Life Sciences Sector
London, UK

Read more »

Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits of ReCell®

Northridge, CA, Perth, Australia and London, United Kingdom – Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that three presentations about the clinical benefits of its product ReCell® had been delivered at the French Society of Plastic, Reconstructive and Aesthetic Surgery meeting, which took place in Paris, France on 24-26 November.

Read more »

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3

Paris, France and Cambridge, Massachusetts, USA – Nanobiotix (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides an update on the global development of its lead product, NBTXR3, across all indications.

Read more »

Imperial Innovations: Portfolio company TopiVert receives IND approval for TOP1630 in the treatment of dry eye syndrome

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) notes that portfolio company TopiVert Pharma Ltd ('TopiVert' or the 'Company') has today announced that its Investigational New Drug (IND) application for the evaluation of TOP1630 ophthalmic solution as a treatment of patients with dry eye syndrome (DES) has been approved by the US Food and Drug Administration (FDA).

Read more »

Labiotech Refresh Paris

24 November 2016
Labiotech Refresh Paris
Paris, France

Read more »

AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of 5,335,000 shares of its common stock and warrants to purchase up to an aggregate of 5,335,000 shares of common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock at a combined price to the public of $0.75 per share and accompanying warrant. The warrants will be immediately exercisable at a price of $0.75 per share of common stock and will expire five years from the date of issuance. The shares of common stock and warrants will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 22, 2016, subject to customary closing conditions.

Read more »

Management Team Strengthened as Auspherix Drives New Class of Antibacterials Towards the Clinic

Stevenage, UK – Auspherix, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of organogold antibacterials, today announced further strengthening of its Management team, with Dr Neil Miller transitioning to Chief Executive Officer (CEO) from Chief Scientific Officer (CSO), and the Company announcing two new appointments of Dr Richard Rutter as CSO and Dr Paul King as Head of Chemistry.

Read more »

Independent clinical study shows Adherium’s Smartinhaler™ dramatically improves clinical outcomes and medication adherence in children with asthma

Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, announces the publication of results from an independent, randomised controlled trial of its respiratory disease management tool, Smartinhaler™. The study, in children with poorly controlled asthma, revealed a significant reduction in hospital admissions over the course of 12 months as well as substantial other health and quality of life benefits.

Read more »

BioBeat16: Stretching Biotech Pharma Entrepreneurship

16 November 2016
BioBeat16: Stretching Biotech Pharma Entrepreneurship
Cambridge, UK

Read more »

World Antibiotic Awareness Week 2016

14-20 November 2016 - World Antibiotic Awareness Week aims to increase awareness of global antibiotic resistance and to encourage initiatives to avoid the further emergence and spread of antibiotic resistance.

European Antibiotic Awareness Day comes at the end  of the week, on 18 November and is an annual European public health initiative to raise awareness about the threat to public health of antibiotic resistance and the importance of prudent antibiotic use.

Read more »

Nanobiotix revenue for Q3 2016

Paris, France and Cambridge, Massachusetts, USA NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the third quarter of 2016.

Read more »

AdAlta Extends Board with Appointment of US-Based Non Executive Director

MELBOURNE, Australia:  AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development today announced the appointment of San Diego-based Dr Robert Peach as Non-Executive Director effective from 14th November 2016.

Read more »

OBN BioTuesday: Early-Stage R&D Company Showcase Evening

15 November 2016
OBN BioTuesday: Early-Stage R&D Company Showcase Evening
Manchester, UK

Read more »

AmpliPhi Biosciences Announces Settlement of Pending Lawsuit

San Diego, USA – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced the settlement of its pending lawsuit with NRM VII Holdings I, LLC (“NRM”).

Read more »

Xellia Pharmaceuticals Commences Packaging and Distribution Operations at Cleveland Site after Successful FDA Inspection

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received notice from the US Food and Drug Administration (FDA) allowing the Company to commence packaging and distribution of drug products at its Cleveland, Ohio facilities.

Read more »

Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating its Potential Usage as In Situ Vaccine for Cancer at The Society for Immunotherapy of Cancer Annual Meeting

Paris, France and Cambridge, Massachusetts, USA – Nanobiotix (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells.

Read more »

AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update

San Diego - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced financial results for the third quarter ended September 30, 2016.

Read more »

Cell Medica and Baylor College of Medicine expand partnership to develop off-the-shelf CAR-NKT cells for cancer treatment

London, UK and Houston, TX – Cell Medica, a leader in cellular immunotherapy for cancer, has expanded its partnership with Baylor College of Medicine (‘Baylor’) to develop an off-the-shelf allogeneic cell therapy, taking advantage of the unique aspects of invariant natural killer T (NKT) cells.

Read more »

Innovative Regenerative Approach to Healing Diabetic Foot Ulcers Now Being Trialed at Two Additional UK sites

London, United Kingdom, Perth, Australia and Northridge, CA – Treatment is now underway at three UK hospitals to trial an innovative approach of using a patient’s own cells to close foot ulcers amongst diabetics, an affliction that leads to some 140 amputations per week across Britain.

Read more »

DNAe to Present New Data on G-BSI Blood-to-Result Test for Rapid Identification of Bloodstream Infections at AMP 2016

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology, announces that Vice President, Product Management, Dr Meghan Norvell, will present new data on the rapid detection of bloodstream infections directly from whole human blood samples at the Association for Molecular Pathology (AMP) 2016 Annual Meeting, in Charlotte, NC.

Read more »

Agendia’s proven breast cancer recurrence assay, MammaPrint, now available in the Middle East

Agendia signs partnership agreement with Cryogene and Mist for Middle East distribution

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today a partnership agreement to distribute the company’s breast cancer recurrence assay, MammaPrint®, in the Middle East. Agendia has signed the distribution partnership agreement with Cryogene S.A.R.L., a healthcare and diagnostics business company specializing in Personalized Medicine Oncology, and its sister company Mist S.A.L.

Read more »

Evaluate Ltd Receives Significant Investment from HgCapital to Expand Products and Services

LONDON, BOSTON, SAN FRANCISCO, TOKYO — Evaluate Ltd, the life sciences commercial intelligence firm, today announced that it has received significant investment from HgCapital’s Mercury Fund to support the Company’s strategic growth plans.  Financial terms have not been disclosed.

Read more »

NG Biotech To Unveil Next Generation Integrated hCG Rapid Diagnostic Blood Test, Developed In Conjunction With Atomo Diagnostics

Guipry, France and Sydney, Australia - French biotechnology company, NG Biotech, and Australian medical device innovator, Atomo Diagnostics, announced today that they have developed the world’s first fully-integrated blood-based rapid test for detection of hCG levels in pregnancy.  The new product, NG-Test® Blood Precision hCG, will be unveiled this month by NG Biotech at Medica 2016 and will be launched commercially early in 2017.

Read more »

AdAlta licenses Alzheimer’s disease-specific shark antibodies to Crossbeta Biosciences for therapeutic and diagnostic development

Melbourne, Australia, and Utrecht, the Netherlands: AdAlta Limited (ASX: 1AD), a biotechnology company specialising in the discovery and development of protein-based therapeutics, and Crossbeta Biosciences, a biotechnology company with unique technology for therapeutic and diagnostic use in neurodegenerative disorders, today announced their commercialisation agreement.

Read more »

Appointment of Chief Executive Officer

Melbourne, Australia - Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced the appointment of Kathy Harrison, current General Manager of Dimerix Biosciences Pty Ltd (operating subsidiary of Dimerix Limited), to the role of Chief Executive Officer of Dimerix Limited.

Read more »

AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology

Melborne, Australia and Freising, Germany - AdAlta Ltd (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, and XL-protein GmbH, a privately owned German biopharmaceutical company specialized in the design of biobetters with extended half-life, announced today that they have entered into a collaboration on the development and commercialization of a long acting form of AD-114, a novel first-in-class drug candidate for fibrosis therapy.

Read more »

BIO Europe

7 – 9 November 2016
BIO Europe
Cologne, Germany

Read more »

Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine

Groningen, the Netherlands – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, today announces the start of a first-in-human study of its intranasal Respiratory Syncytial Virus (RSV) vaccine candidate, SynGEM®, at Imperial College London’s Clinical Research Facility.

Read more »

Instinctif Partners Managing Partner Sue Charles Named in 50 Movers and Shakers in BioBusiness 2016

London, UK: Sue Charles, Managing Partner of Instinctif Partners Life Sciences practice has been named as one of most inspirational women working in Life Sciences in the 50 Movers & Shakers in BioBusiness 2016 report, which was launched today.

Read more »

GE Healthcare and Valneva Collaboration Delivers Optimized Cell Culture Medium for Vaccine Production

Chalfont St. Giles, UK and Lyon, France – GE Healthcare’s Life Sciences business and Valneva SE, a fully integrated vaccine biotech company, are sharing the results of a successful collaboration to optimize virus productivity in Valneva’s EB66® cell-line, a proprietary technology for the production of a wide variety of vaccines, including human and animal health vaccines.

Read more »

Agendia Announces the Award of a New Category 1 CPT Code from the American Medical Association for the MammaPrint® 70-Gene Breast Cancer Recurrence Assay

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that the American Medical Association (AMA) has granted a Category I, MAAA Current Procedural Terminology (CPT) Code for the MammaPrint 70-Gene Breast Cancer Recurrence Assay.

Read more »

AmpliPhi Biosciences Granted Small and Medium Enterprise Status by European Medicines Agency

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that it has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).

Read more »

GE Healthcare enhances single-use manufacturing capabilities with facility expansion and automation

CHALFONT ST. GILES, UK – GE Healthcare’s Life Sciences business, a global provider of expertise, tools and technologies to the biotech industry, announced today a USD 7 million expansion project at its single-use technology manufacturing facility in Westborough, MA, US. The expanded site will manufacture a range of single-use products, including cell growth bags, based on a newly developed film platform resulting from GE’s strategic alliance with Sealed Air.

Read more »

Atomo Diagnostics Receives Grant to Develop New, Innovative HIV Self-Test Solution

Seattle, USA and Sydney, Australia - Medical device innovator Atomo Diagnostics today announced it is the recipient of a US$2.6 million (A$3.6 million) grant from the Bill & Melinda Gates Foundation to develop a next-generation HIV self-test. The grant will support development of an affordable, reliable and simple HIV rapid diagnostic test that will enable people in resource-poor countries to test themselves. Combined with recent equity funding from New York based Global Health Investment Fund, this grant funding enables Atomo to continue to strengthen its position as a leader in the provision of low cost solutions delivering best-in-class usability, reliability and safety to countries most affected by the HIV pandemic.

Read more »

Agendia Expands its Business Activities in Germany

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the expansion of its business activities in Germany. The Company has launched the “BRIDGE” patient initiative to enable more physicians and their patients to access the additional benefits of its MammaPrint test.

Read more »

FierceBiotech - R&D Challenges: A UK Perspective

27 October 2016
FierceBiotech – R&D Challenges: A UK Perspective
London, UK

Read more »

AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections in patients suffering from chronic rhinosinusitis (CRS). Enrollment in the trial has been completed and the Safety Monitoring Committee overseeing the trial has determined that AB-SA01 was well-tolerated by all nine patients and that there were no drug-related serious adverse events.

Read more »

Seventure Partners to Lead Microbiome Session at Bio-Europe 2016

Paris, France - Seventure Partners, one of Europe’s leaders in financing innovation, today announces that for the second year running it is leading a panel at this year’s Bio-Europe conference, taking place 7-9 November in Cologne, Germany.

Read more »

Clinigen and BTG extend global partnership with new exclusive Global Access agreement

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that its Idis Global Access (GA) division, has signed an exclusive supply agreement with BTG plc (LSE: BTG), a specialist healthcare company, to manage BTG’s critical care portfolio across the whole of Europe and now into new territories in Asia.

Read more »

Abzena makes two senior executive appointments to drive growth of international business

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces that John Manzello and Sven Lee have taken up senior executive appointments with Abzena in the US as President, Abzena US and Chief Business Officer, respectively.

Read more »

Imperial Innovations: Portfolio company Veryan Medical announces the completion of subject enrolment into the MIMICS-2 clinical study

London, UK - Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) notes that portfolio company Veryan Medical (‘Veryan’ or the ‘Company’) has completed enrolment into the MIMICS-2 clinical study of its BioMimics 3D® Self-Expanding Stent System (BioMimics 3D).

Read more »

Adherium Announces Key Technology Patent Granted in US

Adherium Limited (ASX : ADR), a global leader in digital health technologies that address suboptimal medication use in chronic disease, today announced that the US Patent and Trademark Office (USPTO) has granted a key patent covering medication adherence monitoring devices that include an optical dose counter.

Read more »

Avita Medical’s ReCell® devices now treating burns in South Africa and Benelux

Northridge, CA, Perth, Australia and London, United Kingdom — Avita Medical Ltd, (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects, has identified distribution partners for its medical devices in South Africa and the three Benelux nations, the Company said today.

Read more »

Synaffix Enters into a Commercial License Agreement with ADC Therapeutics

AMSTERDAM, NETHERLANDS – Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies.

Read more »

UK Bioscience Forum 2016

20 October 2016
UK Bioscience Forum 2016
London, UK

Read more »

AdAlta to present at forthcoming industry conferences

MELBOURNE, Australia: AdAlta Limited (ASX: 1AD), the biotechnology company focused on advancing its lead i-body candidate towards clinical development today announced Chief Executive Officer Sam Cobb will be presenting at and attending a number of key forthcoming conferences to raise awareness with potential investors and partners.

Read more »

U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries

Northridge, CA, Perth, Australia and London, United Kingdom – The U.S. Food and Drug Administration has approved a further increase in the number of patients who can be treated in the United States with the ReCell® regenerative medical device under special compassionate use protocols, Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) said today.

Read more »

Crescendo Biologics Appoints Theodora Harold as Chief Financial Officer

Cambridge, UK – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody® therapeutics, today announced the appointment of Theodora Harold as Chief Financial Officer.

Read more »

Clinigen launches Japanese business to strengthen Asian presence

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The establishment of Clinigen KK further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015.

Read more »

Agendia Appoints Three Leading Cancer Physicians to Its Medical Advisory Board

Irvine, CA, USA and Amsterdam, the Netherlands -- Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today the appointment of three new members to its Medical Advisory Board.

Read more »

AmpliPhi Biosciences Appoints Dr. Carrie-Lynn Langlais Furr as Vice President of Regulatory Affairs and Program Management

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that Carrie-Lynn Langlais Furr, Ph.D., RAC, has been appointed as the Company’s Vice President of Regulatory Affairs and Program Management.

Read more »

Hookipa Secures ‎EUR 4.16 million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies

Vienna, Austria - Hookipa Biotech AG, a biotech company pioneering a new class of immunotherapeutics and vaccines based on its proprietary arenavirus vector platforms, today announces the award of a fifth major grant from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft, FFG), the leading public funding agency for translational research in Austria.

Read more »

Bespak Launches Syrina™ AR 2.25 Auto-Injector for Fully-Automatic Delivery of Viscous Drug Formulations

Cambridge, UK – Bespak, a full-service drug delivery partner specialising in innovative medical devices, today announces the launch of the Syrina™ AR 2.25 auto injector. This innovative auto-injector is the latest addition to the VapourSoft™-powered Syrina range and is suitable for delivering volumes of up to 2ml using a standard 2.25ml pre-filled syringe. The Syrina AR 2.25 provides patients with a fully-automatic two-step, compact device for the self-administration of viscous drug formulations.

Read more »

Worldwide Medtech Sales Forecast to Reach $529.8 Billion by 2022

London, Boston, Tokyo, San Diego – The total value of the global medtech market is expected to reach $529.8 billion by 2022, growing at an annual rate of 5.2 percent over the next seven years according to the “EvaluateMedTech World Preview 2016, Outlook to 2022” report from life science commercial intelligence firm Evaluate Ltd.

Read more »

Consort Medical closes Syrina™ Auto-Injector Master Development Agreement

Hemel Hempstead, UK - Consort Medical plc (“Consort Medical”, “Consort”) (LSE: CSRT), is pleased to announce that Bespak has entered into a master development agreement including key commercial supply terms with a leading global biopharmaceutical company (“Company”). The agreement is focused on Bespak’s novel Vapoursoft™ driven auto-injector technology, Syrina™.

Read more »

The AIM Awards 2016

13 October
The AIM Awards 2016
London

Read more »

AdAlta update on Orphan Drug Designation application for lead drug targeting idiopathic pulmonary fibrosis

MELBOURNE, Australia: AdAlta Limited (ASX: 1AD) has received correspondence from the US Food & Drug Administration (FDA) regarding the development path towards Orphan Drug Designation approval for its lead drug candidate AD-114, targeting idiopathic pulmonary fibrosis (IPF).

Read more »

Imperial Innovations Group plc: Year-end results

London, UK - Imperial Innovations Group plc (AIM: IVO, “Innovations” or “the Group”), a leading technology commercialisation and investment group, has published its results for the year ended 31 July 2016.

Read more »

Dr. Torsten Mummenbrauer Appointed SVP Business Development & Licensing of Hookipa Biotech

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies and vaccines, today announces the appointment of Torsten Mummenbrauer, Ph.D. as Senior Vice President (SVP) Business Development & Licensing. The appointment is effective October 1, 2016.

Read more »

Portfolio company Crescendo Biologics signs collaboration and licence agreement with Takeda worth up to $790m

London, UK - Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) notes that portfolio company Crescendo Biologics Limited (‘Crescendo’ or the ‘Company’), the drug discovery and developer of Humabody®-based therapeutics, has announced a global, strategic, multi-target collaboration and licence agreement with Takeda Pharmaceutical Company Ltd (‘Takeda’) worth up to $790 million.

Read more »

Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m

Cambridge, UK, Cambridge, Mass. and Osaka, Japan – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody®-based therapeutics, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced a global, strategic, multi-target collaboration and license agreement for the discovery, development and commercialization of Humabody® -based therapeutics for cancer indications with a high unmet medical need.

Read more »

Imperial Innovations: First patients dosed in TopiVert’s Phase IIa proof-of-concept study in moderate to severe ulcerative colitis

London, UK - Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) is pleased to note that portfolio company TopiVert Pharma Ltd (‘TopiVert’ or the ‘Company’) has today announced that the first patients have been dosed in its Phase IIa proof-of-concept study to evaluate the safety/tolerability and efficacy of a rectal formulation of TOP1288 in symptomatic ulcerative colitis (UC) patients with moderate to severe disease activity.

Read more »

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

Oxford, UK – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237.

Read more »

Biotech Capital

4 October 2016
Biotech Capital
London, UK

Read more »

Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations

Paris, France and Cambridge, Massachusetts – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noёl Kurdi as the Director of Investor Relations.

Read more »

Interim analysis supports continued development of DMX-200 for the treatment of Chronic Kidney Disease

MELBOURNE, Australia:  Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company, today announced a positive analysis of the interim clinical data from part A of it's phase 2 study in patients with chronic kidney disease.

Read more »

Instinctif Partners named UK PR Consultancy of the Year at the 2016 Corporate and Financial Awards.

In a continued run of award success, Instinctif Partners has been named UK PR Consultancy of the Year at the 2016 Corporate and Financial Awards. Its work for its clients was also recognised in five categories. The Corporate and Financial Awards recognise and celebrate excellence in all aspects of business communication.

Read more »

Puridify named as finalist for two prestigious bioprocess industry awards

London, UK – Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, has been announced as a finalist for two BioProcess International Awards.  These prestigious industry awards recognize the outstanding people, organizations, and technologies that define excellence and that have changed the status-quo by enabling more effective, less expensive biotherapeutic development and manufacturing.

Read more »

BARDA Awards $51.9 Million Contract to DNAe to Develop Semiconductor DNA Sequencing Platform for Rapid Diagnosis of Antimicrobial Resistant Infections and Influenza

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology and developers of a revolutionary blood-to-result test for bloodstream infections, announces that the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) has awarded the Company a contract worth up to $51.9 million to develop its sequencing platform for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

Read more »

Avita Medical Signs Exclusive Distributor Deal in Iran

Northridge, CA, Perth, Australia and London, United Kingdom — A dedicated clinic for Avita Medical’s regenerative medical devices will soon open in Iran following the appointment of an exclusive distributor in this significant aesthetic market, the Company (ASX: AVH), (OTCQX: AVMXY), said today.

Read more »

GE Healthcare opens USD 7.4 million APAC Fast Trak Bioprocessing Technology and Training Center in South Korea

Chalfont St. Giles, UK and Songdo, Korea – GE Healthcare’s Life Sciences business, a global provider of technologies and expertise to the biopharmaceutical and life sciences industries, announced today the opening of a GE Fast Trak Center in Songdo, Incheon Metropolitan City, South Korea.  The new USD 7.4 million Center will support the growth of South Korea’s rapidly expanding biopharmaceutical industry by providing hands-on practical training, technology evaluation, manufacturing support, and consultancy services in the latest strategies and technologies for upstream and downstream bioprocessing.

Read more »

2016 BioCap Conference

29 September 2016
2016 BioCap Conference
Alderley Park, Cheshire, UK

Read more »

Seventure Partners Life Sciences Update for May – September 2016

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, today announces its corporate update for May to September 2016.

A number of positive milestones for Seventure’s portfolio, both financial and in partnering collaborations, has meant a strong year for Seventure Partners, giving the Company a strong position going into 2017.

Read more »

biospain 2016

28 – 30 September 2016
biospain 2016
Bilbao, Spain

Read more »

Crescendo strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody® therapeutics

Cambridge, UK – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody® therapeutics, has been granted U.S. patent No. 9,439,405 to its novel transgenic mouse platform (Crescendo Mouse) for generating Humabody® drug products.

Read more »

Shaun Chilton to take over as Chief Executive Officer

London, UK - Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services group, has been notified by Peter George that he intends to step down as Chief Executive Officer (‘CEO’) on 11 November 2016. He will continue as a non executive director.

Read more »

Transformational Year Delivers 25% Growth in Adjusted EPS*

London, UK - Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its full year results for the year ended 30 June 2016.

Read more »

OBN BioTuesday: Antibiotic Resistance – the need for integrated strategies to address drug-resistant infections

27 September 2016
OBN BioTuesday: Antibiotic Resistance – the need for integrated strategies to address drug-resistant infections
Cambridge, UK

Read more »

16th Annual Biotech in Europe Forum

27 - 28 September 2016
16th Annual Biotech in Europe Forum
Basel, Switzerland

Read more »

Xellia Pharmaceuticals Expands Croatian Anti-Infective Product and Innovation Capabilities to Tackle Antimicrobial Resistance Crisis

Copenhagen, Denmark and Zagreb, Croatia - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections, has significantly expanded its Product and Innovation R&D team with more than 15 new scientists and added approx. 1,000sqm of new lab space at its purpose-built Centre of Excellence in Zagreb, Croatia.

Read more »

4th Annual MedTech & Digital Health Forum

26 September 2016
4th Annual MedTech & Digital Health Forum
Basel, Switzerland

Read more »

Clinigen Group and Cumberland Pharmaceuticals launch Ethyol® in the U.S.

London, UK - Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a specialty pharmaceutical company, announce today that Cumberland has launched Ethyol® (amifostine) for injection in the U.S.

Read more »

European Biotech Week

European Biotech Week, 26 September – 2 October 2016

The third annual week to celebrate biotechnology in Europe – opportunities to get involved, can be found at European Biotech Week

Read more »

Avita Medical to Hold ReCell® Symposium at Leading European Burns Association Course

Northridge, CA, Perth, Australia and London, United Kingdom – Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today it will host a ReCell® Symposium at the EBA Educational Course, taking place in Birmingham, UK, 26-27 September.

Read more »

Bio-Homecoming 2016

22 September 2016
Bio-Homecoming 2016
Leicester, UK

Read more »

R-Pharm produces biological drugs in Yaroslavl with GE Healthcare's FlexFactory™ manufacturing platform

CHALFONT ST. GILES, UK and YAROSLAVL, RUSSIA –  R-Pharm Group has opened an innovative biopharmaceutical production plant equipped with GE Healthcare’s FlexFactory™ manufacturing platform in Yaroslavl, Russia. R-Pharm’s FlexFactory will support the mass production of biologics and biosimilars focused on treating autoimmune diseases and cancer, and allowing for increased access to these critical therapies for patients in the region.

Read more »

Forbion’s portfolio company Akarna Therapeutics Ltd

Naarden, The Netherlands  – Forbion Capital Partners (“Forbion”), one of the leading Dutch Venture Capital firms investing in world-class healthcare technologies, today announced the acquisition of its portfolio company Akarna by Allergan plc. Allergan obtains rights to AKN-083, Akarna’s lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. 

Read more »

AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients

SAN DIEGO  – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced an update on the progress of its ongoing Phase 1 clinical trial for the treatment of S. aureus infections in patients suffering from chronic rhinosinusitis with AmpliPhi’s proprietary and investigational phage cocktail AB-SA01.

Read more »

Innovations invests £5.1m in Artios Pharma Limited

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has committed £5.1 million to the  £25.0 million Series A funding round of Artios Pharma Ltd. (‘Artios’ or ‘the Company’) a new Cambridge-based private biotech company launched today, focused on the development of novel DNA Damage Response (DDR) cancer therapies.

Read more »

One Nucleus - Network Meeting Cambridge: Communicating Your Story Effectively to the Influential Media

20 September 2016
One Nucleus - Network Meeting Cambridge: Communicating Your Story Effectively to the Influential Media
Cambridge, UK

Read more »

Re-focused, science based and commercially driven with £19.9m of cash

Oxford, UK - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces its half year results for the six months ended 31 July 2016.

Read more »

Announcement from Bespak

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of UCB’s CIMZIA® AutoClicks® Prefilled Pen, which is based on core technology licensed from Bespak, in all approved indications.

Read more »

Bpifrance grants Nanobiotix a €2M interest-free loan to support final development stage of lead product, NBTXR3

Paris, France, and Cambridge, Massachusetts, USA – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of €2M for Innovation (prêt à taux zéro pour l’Innovation - PTZI).

Read more »

AdAlta to present at two new drug therapy conferences next week

Melbourne, Australia - AdAlta Limited (ASX: 1AD), the biotechnology company focused on advancing its lead i-body candidate towards clinical development today announced Chief Scientific Officer Dr Mick Foley will present at the Cambridge Healthtech Institute’s 4th Annual Targeting Ocular Disorders conference on Wednesday September 21 as part of the 14th Annual Discovery of Target conference where he will also present on Thursday September 22 at the Westin Boston Waterfront Hotel in Boston MA USA.

Read more »

Worldwide Prescription Drug Sales Forecast to Grow 6.3% Annually

London, Boston, San Francisco, Tokyo — The combination of increasingly vocal politicians railing against US drug pricing, a weak global recovery, uncertainties created by Brexit, and the outcome of the US presidential race have all coalesced to create uncertainty for investors. However, for those willing to take a longer-term view, the outlook is more nuanced, with a projected compound annual growth rate of 6.3 percent in global prescription sales over the next six years according to the EvaluatePharma World Preview 2016, Outlook to 2022 report from life science market intelligence firm, Evaluate Ltd.

Read more »

AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections. A safety committee reviewed the trial data and concluded AB-SA01 was well-tolerated by subjects in the trial and there were no drug-related serious adverse events.

Read more »

AmpliPhi Biosciences to Participate in Upcoming Conferences

SAN DIEGO  - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that company management will participate in two upcoming scientific and investor conferences:

Read more »

Directorate change

Cambridge, UK  – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that non-executive director, Anker Lundemose, will step down from the board at the end of September to enable him to commit more time to his other roles, particularly as CEO of Mission Therapeutics. 

Read more »

Abzena: AGM business update

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes a business update for the period to 13 September 2016, ahead of its AGM being held at 10am today at the Group’s Cambridge office.

Read more »

Wear Jeans, Change Lives, Jeans for Genes Day, Friday 23 September 2016

For over 10 years Instinctif Partners has supported Jeans for Genes Day. On Friday 23 September we will once again be leaving our suits at home and wearing jeans to help to raise money for this great cause – helping to fund the vital care and support services that transform the lives of 1 in 25 children also inherit a genetic disorder that makes their life very difficult.

Read more »

AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate

Melbourne, Australia - AdAlta Limited (ASX: 1AD), the biotechnology company specialising in the discovery and development of protein-based therapeutics has entered an agreement with FujiFilm Diosynth Biotechnologies to manufacture AdAlta’s lead drug molecule for the treatment of idiopathic pulmonary fibrosis.

Read more »

AmpliPhi Biosciences’ Bacteriophage Cocktail Shown to Prevent C. difficile Biofilm Formation and Reduce Colonization

San Diego, USA – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced the publication of data from a preclinical study conducted by its collaborators at the University of Leicester demonstrating the prophylactic efficacy of AmpliPhi's proprietary phage cocktail, in vitro and in vivo, for the treatment and prevention of Clostridium difficile (C. difficile) infections.

Read more »

Recent announcement from Bespak

Bespak and AstraZeneca have signed scale-up and supply agreement for proprietary pressurised metered dose inhaler technology.

The resulting respiratory devices (AZ’s Bevespi Aerosphere) will be used to treat COPD.

Read more »

One Nucleus BioWednesday: Securing Investment and Partners in the US

7 September 2016
One Nucleus BioWednesday: Securing Investment and Partners in the US
London, UK

Read more »

Biotech and Money Awards 2016 Winners

Instinctif Partners congratulates its clients, Clinigen and Immunocore on winning awards at the inaugural Biotech and Money Gala Dinner on 6th September 2016 at Gibson Hall, London.

Congratulations also to all those shortlisted for an award, including our clients Abcam, Abzena, Autifony, Auspherix, Karus Therapeutics, Novabiotics and Puridify.

Read more »

Instinctif Partners congratulates its clients on winning inaugural Biotech and Money awards 2016

London, UK: The Life Sciences practice at Instinctif Partners, the business communications consultancy, congratulates its clients Clinigen Group plc (‘Clinigen’) and Immunocore for winning awards at the Biotech and Money Gala Dinner.

Read more »

Biotech and Money Assembly and Awards Gala Dinner

6 September 2016
Biotech and Money Assembly and Awards Gala Dinner
London, UK

Read more »

Avita Medical’s Regenerative Skin Technology significantly reduces burn scars and healing time

Data presented at the International Society of Burn Injuries Congress, Miami, USA

Read more »

Biotech & Money Awards 2016

Instinctif Partners was delighted to be on the Biotech and Money Advisory Board and 2016 Awards executive judging panel in June - looking forward to the Awards Gala Dinner on the 6 September at the Gibson Hall, London.
Good luck to all the finalists, including our clients Abcam, Abzena, Auspherix, Autifony, Clinigen, Immunocore, Novabiotics and Puridify.

Read more »

Adherium expands its international presence with Mr Thomas Lynch as Chairman & Dr Doug Wilson as Medical Director

Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced Mr Thomas Lynch as Adherium’s new Chairman, and Dr Doug Wilson as Adherium’s executive Medical Director.

Read more »

Nanobiotix half year results for the six months ended 30 June 2016

Paris, France, and Cambridge, Massachusetts, USA – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its half year results for the six months ended 30 June 2016 and outlines its updated share capital breakdown as of 30 June 2016.

Read more »

AdAlta Receives Australian Government Grant to Advance Understanding of Potential New Lung Fibrosis Therapy

Melbourne, Australia: Biotechnology company AdAlta Limited (ASX: 1AD), specialising in the discovery and development of protein-based therapeutics has received a AU$50,000 Innovation Connections Grant From the Australian Federal Government to support research with The Alfred Hospital and La Trobe University in Melbourne.

Read more »

Cell Medica collaborates with UCL to develop modified T cell receptor products for cancer treatment

London, UK – Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, has signed a research collaboration with UCL (University College London) aiming to utilize UCL’s novel T cell receptor (TCR) technology to generate leading-edge modified TCR products for the treatment of cancer.

Read more »

Cell Medica and UCL collaborate to develop modified T cell receptor products for the treatment of cancer

Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) notes today’s announcement by portfolio company Cell Medica (the ‘Company’) of a new research collaboration with UCL (University College London) which will see the Company utilise UCL’s novel T cell receptor (TCR) technology to generate leading-edge modified TCR products for the treatment of cancer.

Read more »

GE Healthcare expands cell therapy portfolio with license of STEMCELL Technologies’ T-Cell reagents

Exclusive licensing agreement will provide cGMP grade reagents to further enable development and manufacturing of cellular immunotherapies

Read more »

AdAlta IPO to Accelerate New Therapy for Lung Fibrosis

Melbourne, Australia – Biotechnology company AdAlta Limited (ASX: 1AD), specialising in the discovery and development of protein-based therapeutics is pleased to advise that it will commence trading on the Australian Securities Exchange (ASX) on Monday 22 August after its $A$10 million IPO closed oversubscribed.

Read more »

GE Healthcare and Sealed Air enter an exclusive agreement to deliver film for single-use bioprocess systems

CHALFONT ST. GILES, UK and CHARLOTTE, NC – GE Healthcare’s Life Sciences business, a global provider of technologies and expertise to the biopharmaceutical and life sciences industries and Sealed Air Corporation, a global manufacturer of primary films for pharmaceutical solutions, today announced the expansion of a strategic alliance designed to further the development and innovation in the biopharmaceuticals industry.

Read more »

Pharma and Medtech Sectors Struggle in First Half of 2016

LONDON, BOSTON, SAN FRANCISCO, TOKYO — Falling stock markets, political uncertainty and continued global economic weakness all contributed to a mixed first half for the pharma and medtech industries. While M&A activity and drug approvals remained buoyant, falling equity markets in the first six months of the year had a clear impact on IPO and venture financing for pharma. Similarly, the first half of 2016 saw no end to the worrying developments in the medtech industry, with the venture crisis worsening and the IPO window all but shut. The second half promises further turmoil with nervousness growing ahead of the U.S. presidential elections - both candidates have promised to train their sights on the healthcare sector - according to first half reviews of 2016 from EP Vantage, the editorial arm of life science market intelligence firm Evaluate Ltd.

Read more »

AmpliPhi Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update

San Diego - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the second quarter ended June 30, 2016.

Read more »

Drug Discovery Company AdAlta Raises AUD$10m in Over-Subscribed Australian IPO to Accelerate New Therapies for Lung Fibrosis

Melbourne, Australia - AdAlta Limited (ASX: 1AD), the biotechnology company specialising in the discovery and development of protein-based therapeutics has closed its AUD$10 million initial public offering (IPO) on the Australian Securities Exchange (ASX) following strong support from investors, including a number of leading investment funds and existing shareholders. The offer was oversubscribed.

Read more »

AmpliPhi Biosciences Confirms Clinical Trial Progress and Announces Upcoming Conference Call to Provide Corporate Update and Discuss Second Quarter 2016 Financial Results on August 15, 2016

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today reported on the continued advancement of its two Phase 1 trials for AB-SA01 and announced that it will host a conference call to report financial results for the second quarter ended June 30, 2016 on Monday, August 15, 2016 at 4:30 p.m. EDT.

Read more »

AmpliPhi Biosciences Granted Japanese Patent Covering the Use of Phage Therapy to Resensitize Pseudomonas aeruginosa Infections to Antibiotics

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that the Japanese Patent Office has granted AmpliPhi a patent for the “Beneficial effects of bacteriophage treatments” targeting Pseudomonas aeruginosa (Pseudomonas) infections. A corresponding patent has been granted in the United States and is currently being prosecuted in Canada. Additional patents with broader bacterial species claims have been granted in the European Union and Australia.

Read more »

AmpliPhi Biosciences Completes Enrollment of its Investigational Phage Therapy Trial Targeting Staphylococcus aureus

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has completed enrollment of its Phase 1 clinical trial to evaluate the safety of AB-SA01, its proprietary phage cocktail targeting Staphylococcus aureus (S. aureus) infections. The trial is being conducted under a Collaborative Research and Development Agreement with the U.S. Army at the Walter Reed Army Institute of Research (Walter Reed) Clinical Trials Center in Silver Spring, Maryland. AmpliPhi expects to report topline results by the end of the third quarter of 2016.

Read more »

Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA

Melborne, Australia - Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced it has received the minutes from the pre-IND meeting held with the US Federal Drug Administration (FDA) on the 29th June 2016.

Read more »

Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia

London, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of the central nervous system, today announced successful completion of a Phase I clinical evaluation of its Kv3 modulator, AUT00206.

Read more »

Trod Medical Receives a New Patent Allowance for Prostate Focal Therapy Encage Device

Leuven, Belgium – Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office (USPTO), entitled “Method to remove a tumor using a percutaneous surgical instrument”.

Read more »

Dimerix Announces Pre-clinical Program, DMX-250, Targeting Heterodimers active in NASH, a major Liver Disease

MELBOURNE, Australia - Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary assay technology, today announced a second development program, DMX-250, targeting fibrosis in patients with Non-Alcoholic Steatohepatitis (NASH).

Read more »

Faron enters into an agreement with Abzena for the manufacture of Clevegen®

Turku, Finland and Cambridge – Faron Pharmaceuticals Ltd (AIM: FARN) (“Faron”), a clinical stage biopharmaceutical company, and Abzena plc (AIM: ABZA), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announce that they have entered into an agreement whereby Abzena will manufacture Clevegen®, a novel therapeutic antibody being developed by Faron to reduce immune suppression in cancer.

Read more »

GE Healthcare - Achieve shorter run times with Superdex™ 75 Increase size exclusion chromatography columns

New Product Announcement
Superdex™ 75 Increase from GE Healthcare’s Life Sciences business is a new-generation size exclusion chromatography (SEC) resin for fast, reproducible, and high resolution small-scale purification and analysis of recombinant tagged proteins. Compared with predecessor products, Superdex 75 Increase prepacked columns offer runtimes reduced to one-third with maintained resolution, or up to 50% higher resolution for improved purity and analysis.

Read more »

Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine

Vienna, Austria, 20 July 2016 - Hookipa Biotech AG, a company pioneering a new class of immunotherapies and vaccines, based on its proprietary viral vector platform Vaxwave®, today announces the start of a first-in-human study to evaluate the safety and immunogenicity of its vaccine candidate, HB-101, against human cytomegalovirus (HCMV). Part of the herpes family of viruses, HCMV is one of the most significant viral pathogens during pregnancy and in immunocompromised patients.

Read more »

Cell Medica - Lead cancer immunotherapy candidate granted EU orphan drug designations

London, UK– July 20, 2016. Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, has received European Commission orphan drug designations for CMD-003 (baltaleucel-T) as a treatment for extranodal NK/T-cell lymphoma, nasal type, and post-transplant lymphoproliferative disorder.

Read more »

Clinigen Group - Year end trading update

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides a trading update for the 12 months ended 30 June 2016.

Read more »

Abzena and Baylor Scott & White Research Institute team up to form Denceptor Therapeutics to develop novel immunotherapies

Cambridge, UK and Dallas, US – Abzena plc (AIM: ABZA, “Abzena” or the “Group”) and the Baylor Scott & White Research Institute announce the formation of a joint venture company, Denceptor Therapeutics Limited (“Denceptor”).

Read more »

Nanobiotix revenue for Q2 2016

Paris, France and Cambridge, Massachusetts, USA – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the second quarter of 2016.

Read more »

Cell Medica acquires Delenex Therapeutics

London, UK – Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics.

Read more »

Cell Medica acquires Delenex Therapeutics AG to expand T Cell immunotherapy programme

Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) notes today’s announcement by portfolio company Cell Medica (the ‘Company’) of its acquisition of Delenex Therapeutics AG (‘Delenex’) based in Schlieren, Switzerland.

Read more »

Avita Medical announces Rights Issue raises AU$9 million

Northridge, CA and Cambridge, United Kingdom, Perth, Australia – Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY) today announced it has raised AU$9 million in a partially underwritten Rights Issue to support the Company’s strategy to launch in the US and push forward with product commercialization.

Read more »

Australian Drug Discovery Company AdAlta, Announces IPO to Accelerate New Therapies for Lung Fibrosis

Melbourne, Australia - AdAlta Limited, the biotechnology company specialising in the discovery and development of protein based therapeutics is seeking to raise up to AU$10 million in an initial public offering (IPO) on the Australian Securities Exchange to fund clinical studies with its lead compound (AD-114) which shows promise in treating fibrosis.

Read more »

BIA Summer Networking Reception

7 July 2016
BIA Summer Networking Reception
London, UK

Read more »

GHO Capital & Ardian team with Envision leadership to acquire the Envision Pharma Group from the Halifax Group

London, UK – GHO Capital, the European specialist investor in healthcare, in collaboration with Ardian, the independent private investment company, has partnered with the Envision Pharma Group’s (“Envision”) leadership team to acquire Envision, a leading Medical Affairs-focused scientific communications and technology solutions provider, from the Halifax Group.

Read more »

Econic raises £5m to develop novel catalyst technology

Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) announces that portfolio company Econic Technologies ('Econic' or the ‘Company’) has completed a £5.0 million funding round.

Read more »

BioGeneration Ventures announces first close of its third fund

Naarden  – BioGeneration Management III B.V. (“BGV”) announces the first close of its new venture capital fund, BioGeneration Capital Fund III C.V. with a target fund size of EUR 50 million.

Read more »

Multiplex immunoassays with Firefly® particle technology

Cambridge, UK - Abcam’s multiplex immunoassays combine unique Firefly® hydrogel technology with Abcam’s high-performance antibodies to simultaneously measure up to 75 different proteins in a mere 12.5 µL of sample. With sensitivity below 1 pg/mL, the assay can provide rapid multiplex data within hours1, even in complex matrices with low target concentrations.

Read more »

Auspherix Appoints Experienced Anti-Infectives Clinician to Scientific Advisory Board

Stevenage, UK – Auspherix, an early stage anti-infectives company, today announces that it has expanded its Scientific Advisory Board (SAB) with the appointment of highly experienced clinician, Professor William Hope.

Read more »

Avita Medical scoops One Nucleus Summer BioNewsRound Award 2016

Cambridge, UK: As announced at ON Helix 2016, Avita Medical is this year’s winner of the coveted One Nucleus Summer BioNewsRound Award.

Read more »

PsiOxus and Bristol-Myers Squibb announce combination study and Immuno-Oncology clinical collaboration

Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) notes today’s announcement by portfolio company PsiOxus Therapeutics (‘PsiOxus’ or the ‘Company’) of an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo® (nivolumab) to treat a range of tumour types in late-stage cancer patients.

Read more »

First-In-Human Study Of Immbio’s Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine To Be Safe And Immunogenic

Cambridge, UK — ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, reports positive results from the First-in-Human study of its novel vaccine, PnuBioVax™, against the bacterial pathogen Streptococcus pneumoniae (NCT02572635). PnuBioVax was found to be safe and well tolerated, and capable of producing antibody responses against key S. pneumoniae antigens broadly conserved across strains. The data was presented today at the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Glasgow, UK.

Read more »

LaingBuisson appoints Stephen Dorrell as Chairman

LaingBuisson, the UK’s leading healthcare market intelligence provider, today announces the new appointments of The Right Honourable Stephen Dorrell as Chairman and Henry Elphick as CEO.

Read more »

Clinigen and Horizon Pharma enter partnership to initiate European Managed Access program for RAVICTI® (glycerol phenylbutyrate) Oral Liquid

Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Horizon Pharma plc (NASDAQ: HZNP), have initiated a Managed Access program in Europe for Horizon’s RAVICTI® (glycerol phenylbuterate) Oral Liquid.

Read more »

Avita Medical Appoints a leading Health Economics Group

Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Limited (ASX:AVH; OTCQX:AVMXY) has engaged a leading Health Economics Group to evaluate how its novel regenerative medical device, ReCell®, can save money at US burns centres, the Company said today.

Read more »

Regenerative Medicine Publishes Key Findings from Avita Medical’s 2016 Skin Regeneration Symposium

Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom — Avita Medical’s autologous skin healing technology shows strong effectiveness in treating burns, chronic wounds and aesthetics, and will help strained public health budgets, according to a comprehensive review of data presented at a scientific symposium by a leading Regenerative Medicine journal, the Company said today

Read more »

Storm Therapeutics raises £12m to develop novel cancer therapeutics

Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) announces that portfolio company Storm Therapeutics (or the ‘Company’) has completed a £12.0 million Series A fundraising which will be used for the identification of small molecules that target RNA-modifying enzymes as the basis for the development of new cancer therapies.

Read more »

ON Helix 2016

28 June 2016
On Helix 2016   
Cambridge, UK

Read more »

Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms

Read more »

Brexit – Communications priorities

On 23 June the UK voted in a referendum to leave the EU. As this process and its ramifications unfold over the coming months and years, Instinctif Partners is helping its clients to steer their businesses successfully through this period of change and uncertainty.

Keep calm and read on

Read more »

Avita Medical Awarded US$7.96m in BARDA Extension Deal

Northridge, CA, Perth, Australia and Cambridge, United Kingdom - A US Federal authority charged with supporting development of medical countermeasures for possible mass casualty events has agreed to fund Avita Medical a further $US7.96 million to support the regenerative medicine company in its plans for US market approval and product launch of ReCell®, the Company said today.

Read more »

ImmBio Selected for an Oral Presentation at the 10th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD-10)

Cambridge, UK — ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, today announces that Development Director, Dr Chris Bailey, has been invited to orally present new data from the company’s First-in-Human phase I clinical study evaluating its novel pneumococcal vaccine candidate, PnuBioVax, at the 10th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD-10), Glasgow, Scotland, 26-30 June. The Company is also presenting three posters.

Read more »

Biotech and Money Awards Executive Judging Panel

Instinctif Partners is delighted to be on the Biotech and Money Advisory Board and 2016 Awards executive judging panel.

Read more »

Biotechs and the City Summer

21st June 2016
Biotechs and the City Summer
Instinctif Partners, London

Read more »

Polyganics Announces CE Mark for NEUROCAP®, the Nerve Capping Device for Treatment and Prevention of Symptomatic Neuroma

Groningen, The Netherlands – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has received the CE mark for NEUROCAP®, its nerve capping device. Polyganics intends to launch NEUROCAP® in several European countries later this year.

Read more »

Avita Medical Appoints a COO and a VP of Sales and Marketing

Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Limited (ASX:AVH; OTCQX:AVMXY) has strengthened its operational and commercialisation activities with the appointment of a Chief Operating Officer, and a Vice President of Sales and Marketing, the Company said today.

Read more »

Circassia cat allergy Phase III study

London, UK - Imperial Innovations Group plc (AIM: IVO, "Innovations" or the "Group") notes the publication by Circassia Pharmaceuticals (LSE: CIR, "Circassia" or the "Company"') of top-line results from its investigational cat allergy immunotherapy Phase III study.

Read more »

Cell Medica and Baylor College of Medicine announce Exclusive Licensing Agreement and Co-development Partnership to create next generation cellular immunotherapy products for the treatment of cancer

London, UK and Houston, TX – Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, announced today a ground breaking co-development partnership with Baylor College of Medicine (Baylor) to develop next-generation technologies for engineering immune cells with enhanced functions for the treatment of solid tumors. The collaboration provides Cell Medica with an exclusive license over several Baylor cell and gene technologies and an option to license new products introduced into the co-development partnership by Baylor’s leading research teams in the field of genetically engineered immune cells.

Read more »

Cell Medica and Baylor College of Medicine partner to create next generation cellular immunotherapy products for cancer treatment

Imperial Innovations Group plc (AIM: IVO or ‘the Group’, ‘Innovations’) notes today’s announcement by portfolio company Cell Medica (the ‘Company’) of an exclusive licensing agreement and a co-development partnership with the Baylor College of Medicine (Baylor) to create next generation cellular immunotherapy products for the treatment of cancer.

Read more »

FCF II Co-Invest I supports EUR 22M Series B of Allecra Therapeutics

Munich, Germany and Naarden, The Netherlands - Forbion Capital Partners, the Dutch life sciences venture capital firm, today announced that it has invested from its recent FCF II Co-Invest I fund in Allecra Therapeutics, an existing FCF II portfolio company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections. The round was led by new investor, Delos Capital.

Read more »

Instinctif Partners hosts Biotech and the City Summer event

On Tuesday, 21 June 2016 Instinctif Partners hosted the Biotech and the City Summer event, the main mid-year networking event for Biotech and Money community members. The evening was a great success and served as an informal forum for senior executives to come together, network and enjoy a relaxed evening of great networking with their peers.

Read more »

Jörn Aldag Appointed CEO of Hookipa Biotech

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies and vaccines, today announces the appointment of Mr. Jörn Aldag as CEO.

Read more »

Avita Medical announces non-renounceable rights issue to raise up to approximately AUD$11m

Northridge, CA and Cambridge, United Kingdom, Perth, Australia – Avita Medical Ltd (Company) (ASX: AVH), (OTCQX: AVMXY) today announced a partially underwritten non-renounceable rights issue to raise up to approximately $11m (Rights Issue) to support the Company’s strategy to launch in the US and push forward with product commercialization. Avita manufactures portable cell-harvesting devices that can be used to treat burns, chronic wounds and skin defects.

Read more »

TROD Medical’s Prostate Focal Therapy Device EncageTM Advances in US and UK Clinical Studies

Leuven, Belgium – TROD Medical NV, the medical device company developing tools for focal ablation announces completion of enrollment in its clinical study at two world-renown cancer research institutions, University College London (UCL) and New York University (NYU).

Read more »

Dimerix’s Chief Scientific Advisor Awarded British Pharmacological Society’s Novartis Prize

MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary assay technology, today announced its co-inventor and Chief Scientific Advisor, has won the British Pharmacological Society’s Novartis Prize.

Read more »

Clinigen and Galen enter exclusive Global Access agreement for chemotherapy drug DaunoXome®

First agreement for Clinigen’s Global Access division will provide Healthcare Professionals with on-demand access to DaunoXome® where it is unlicensed at the point of care

Read more »

Full year results: revenues up 74%, strong outlook within growing market

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2016.

Read more »

GE Healthcare launches next generation BiacoreTM molecular interaction analysis platform

Chalfont St. Giles, UK – GE Healthcare’s Life Sciences business today launched the first of a next generation of Biacore systems harnessing Surface Plasmon Resonance (SPR) technology. Biacore 8K marks the start of a new generation of Biacore systems maintaining the high data quality expected from Biacore at high throughput. New design features efficiently address current industry challenges such as understanding complex targets in drug discovery.

Read more »

Instinctif Partners Congratulates Karen Bernstein on Winning the “Mediscience Commentator of the Year” Award 2016

London, UK: Instinctif Partners, the business communications consultancy, is pleased to congratulate Karen Bernstein of  BioCentury for winning the “Mediscience Commentator of the Year” award at the European Mediscience Awards on 9th June 2016, in recognition of her clear and concise commentary on the Life Sciences Sector.

Read more »

NovaBiotics Presents Three New Posters on Anti-Infectives Pipeline at 39th European Cystic Fibrosis Society Conference

Aberdeen, UK – NovaBiotics Ltd (“NovaBiotics” or the “Company”), the Aberdeen-based clinical-stage biotechnology company, announces today that three sets of new data will be presented at this year’s European Cystic Fibrosis (CF) Society Conference, taking place in Basel, Switzerland between 8-11 June.

Read more »

Mediscience Awards Dinner 2016

9 June 2016
Mediscience Awards Dinner
London, UK

Table host: Melanie Toyne-Sewell

Read more »

Clinigen announces partnership with Basilea to initiate a Managed Access program for isavuconazole to treat patients with invasive fungal infections in Europe

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, and Basilea Pharmaceutica International Ltd (‘Basilea’), a Swiss pharmaceutical company focused on providing innovative pharmaceutical hospital products, have initiated a Managed Access program for isavuconazole to treat patients with invasive fungal infections in those European countries where isavuconazole has been approved but is not yet commercially available.

Read more »

PnuVax to acquire inactivated yellow fever vaccine intellectual property from GE Healthcare

CHALFONT ST. GILES, UK and KINGSTON, ONTARIO, CANADA – PnuVax Incorporated (PnuVax), a vaccine and biopharmaceutical company, and GE Healthcare’s Life Sciences business (NYSE: GE) announced today that they have entered an agreement under which PnuVax can acquire GE Healthcare’s intellectual property relating to an inactivated yellow fever vaccine. Under the terms of the agreement, PnuVax will purchase a GE Healthcare Life Sciences FlexFactory™ biomanufacturing platform and the two companies plan a collaboration to optimize the manufacturing process for the new vaccine. Financial terms were not disclosed.

Read more »

New Data Shows Agendia’s MammaPrint® can Prevent Under and Over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score

  • The PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS) included 840 women at 58 US institutions.
  • 45% of patients with an intermediate/indeterminate Recurrence Score from a 21-gene assay OncotypeDx (commercial assay RS 18-31) were reclassified as Low Risk by Agendia’s FDA-cleared 70-gene assay MammaPrint.  90% of physicians adhered to the treatment decisions based on the definitive MammaPrint results.
  • 76% of patients were spared from overtreatment with chemotherapy among the MammaPrint Low Risk patients who were previously indicated to receive chemotherapy based on the indeterminate 21-gene assay results.
  • Based on the recent outcomes from the phase III, prospective, randomized MINDACT trial, it is safe to withhold chemotherapy in MammaPrint Low Risk patients, even in the presence of high risk clinical factors.
Read more »

Avita Medical signs deal for distribution in Malaysia

Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), has furthered its expansion into the Asian market with the appointment of a specialized wound care distributor for its products in Malaysia.

Read more »

NovaBiotics Highlights Importance of a Co-ordinated Approach to Antimicrobial Resistance

New multi-action, multi-strain anti-infectives needed to win battle against AMR

Read more »

Health for Life Capital™ Participates in $50m Financing of Microbiome Company Vedanta Biosciences

Paris, France – Health for Life Capital™, managed by Seventure Partners, one of Europe’s leaders in financing innovation, today announces that it has invested $8m as part of a $50m financing round completed by Boston-based Vedanta Biosciences.

Read more »

BIO International 2016

6-9 June 2016
BIO International 2016
San Francisco, California

Read more »

Shifting CAR-Ts into a Higher Gear

LONDON, BOSTON, SAN FRANCISCO, TOKYO — Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval.

Read more »

2nd Annual Immuno-Oncology: BD&L and Investment Forum

3 June 2016
2nd Annual Immuno-Oncology: BD&L and Investment Forum
Chicago, USA

Read more »

Instinctif Partners Hosts the UK BioIndustry Association Annual Lecture

 

London: On Thursday, 12 May 2016, Instinctif Partners, the business communications consultancy, sponsored and hosted the 2016 UK BioIndustry Association (BIA) Annual Lecture – ‘An evening with Dr Clive Dix’.  The BIA is the trade association for innovative enterprises involved in UK bioscience.

Read more »

AmpliPhi Biosciences to be Granted European Patent Covering the Use of Phage Therapy to Resensitize Bacterial Infections To Antibiotics

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that the European Patent Office has issued a decision to grant AmpliPhi patent No. 2136826, for the “Beneficial effects of bacteriophage treatments”. A corresponding patent has been granted in Australia and a species-specific patent for Pseudomonas aeruginosa has been granted in the United States. Additional patents are pending in Canada, Japan and the United States.

Read more »

Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to their Medical Advisory Board

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the appointment of Gabriel N. Hortobagyi, MD, FACP, FASCO, as Chair of its Medical Advisory Board. Dr. Gabriel Hortobagyi is an internationally recognized expert in clinical and translational research of breast cancer and brings more than 35 years of experience as a Breast Medical Oncologist. He is Professor and Chair Emeritus of the Department of Breast Medical Oncology at the MD Anderson Cancer Center (MDACC) and is also the past President of the American Society of Clinical Oncology (ASCO). He is currently the Chair of the Southwest Oncology Group Breast Committee and a member of the Scientific Advisory Board of The Breast Cancer Research Foundation.

Read more »

AmpliPhi Biosciences Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants

SAN DIEGO - AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the pricing of a registered direct offering of 2,127,660 shares of common stock and warrants to purchase up to an aggregate of 1,063,830 shares of common stock. Each share of common stock is being sold together with a warrant to purchase one-half of a share of common stock of AmpliPhi at a combined purchase price of $2.35. The warrants will be immediately exercisable at a price of $2.25 per full share of common stock for a period of five years from closing, which is expected to occur on June 3, 2016.

Read more »

Nanobiotix receives US$1m milestone payment from PharmaEngine

First patient injected with NBTXR3 in soft tissue sarcoma registration phase in Asia

Read more »

AmpliPhi Biosciences’ CEO to Discuss Novel Approaches to Fighting Drug-Resistant Pathogens in Panel at BIO International

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi’s Chief Executive Officer, will participate in a panel discussion at this year’s BIO International Convention.

Read more »

Clinical Study in UK to Evaluate ReGenerCell™ for Diabetic Foot Ulcer Treatment

• Study will evaluate preliminary safety and effectiveness in a cohort of up to 24 patients
• Innovative regenerative technology will use patients’ own skin cells to try to close chronic Diabetic Foot Ulcer (DFUs)
• DFUs represent a significant new potential patient population for Avita Medical

Read more »

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology

Paris, France, Cambridge, MA, USA – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO).

Read more »

Indegene and TranScrip launch IntraScience - an innovative regulatory, safety and medical services solution for global bio-pharmaceutical companies

Iselin, NJ, USA and Reading, UK - Indegene (www.indegene.com), a leading global provider of clinical, commercial, and marketing solutions to life science, pharmaceutical, and healthcare organisations and TranScrip (www.transcrip-partners.com), a renowned global provider of innovative scientific support throughout the product lifecycle, today announced the extension of their existing alliance with the launch of IntraScience.

Read more »

Knowledge for Growth

26 May 2016
Knowledge for Growth
Ghent, Belgium

Read more »

Xellia Pharmaceuticals Expands Budapest Facilities to Strengthen Anti-infective Product Capabilities

Copenhagen, Denmark, and Budapest, Hungary - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has held an official ground breaking ceremony for a new US$10million  expansion of its Budapest manufacturing facility to include product stability and release testing capabilities.

Read more »

AmpliPhi Biosciences Announces Start of First Phage Therapy Trial in U.S. Under IND

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has dosed the first patient in its Phase 1 clinical trial to evaluate the safety of AB-SA01, AmpliPhi’s proprietary phage cocktail targeting Staphylococcus aureus (S. aureus) infections, administered topically to the intact skin of healthy adults. The trial is being conducted under a Collaborative Research and Development Agreement with the U.S. Army and at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland.

Read more »

Labiotech Refresh

24 May 2016
Labiotech Refresh
Berlin, Germany

Read more »

Cell Medica Expands Management Team with Experienced Pharmaceutical Executives

London, UK and Houston, TX - Cell Medica, a leader in developing, manufacturing and marketing cellular immunotherapies for the treatment of cancer and infections, today announced key appointments to continue strengthening its senior management team.

Read more »

Clinigen expands US presence with opening of new Yardley headquarters

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, officially opened its new US headquarters last night at a reception attended by members of local government, leading pharmaceutical and biotech companies and the US Director of the British Government’s international commercial arm, UK Trade & Investment (“UKTI”).

Read more »

Molecular Diagnostics World Summit 2016

19-20 May 2016
Molecular Diagnostics World Summit 2016
London, UK

Read more »

Synthon Advances Clinical Evaluation of Anti-HER2 ADC SYD985 in an Expanded Cohort of HER2-positive Metastatic Breast Cancer Patients

Nijmegen, the Netherlands  ̶  Synthon Biopharmaceuticals (‘Synthon’) today announced the initiation of the second part of its ongoing Phase I clinical trial with the investigational anti-HER2 antibody-drug conjugate (ADC) SYD985.

Read more »

Nanobiotix revenue for the 1st quarter of 2016

Paris, France, Cambridge, USA – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the first quarter of 2016.

Read more »

Instinctif Partners Hosts UK BioIndustry Association Annual Lecture

London: On Thursday, 12 May 2016, Instinctif Partners, the business communications consultancy, sponsored and hosted the 2016 UK BioIndustry Association (BIA) Annual Lecture – ‘An evening with Dr Clive Dix’.  The BIA is the trade association for innovative enterprises involved in UK bioscience.

Read more »

Agendia Appoints Dr. M. William Audeh to Chief Medical Officer

IRVINE, CA and AMSTERDAM - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, recently announced the appointment of veteran medical oncologist M. William Audeh, MD, MS to the position of Chief Medical Officer.

Read more »

Clinigen Group and Cumberland Pharmaceuticals enter into exclusive U.S. commercialisation agreement for oncology support drug Ethyol®

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a U.S. specialty pharmaceutical company, have signed an exclusive agreement to commercialise the oncology support drug, Ethyol® (amifostine), in the U.S. This is the first product Clinigen has licensed to Cumberland under the strategic alliance entered into late last year.

Read more »

Instinctif Partners Congratulates the Shortlisted Nominees for the European Mediscience Awards 2016

10 May 2016, London: Instinctif Partners, the business communications consultancy, congratulates all of the nominees shortlisted as finalists for the European Mediscience Awards 2016, especially those individuals and companies in the category, Mediscience Commentator of the Year, of which Instinctif Partners is the sponsor, for the eighth year.

Read more »

JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China

GE Healthcare delivers world’s first modular manufacturing solution based on single-use bioprocessing technology in just 18 months

Read more »

Polyganics Announces Enrollment of First Patients in Multicenter Study for NEUROCAP Nerve Capping Device

Groningen, The Netherlands - Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that the first four patients have been enrolled in the “STOP NEUROMA” study.

Read more »

Avita’s novel ReNovaCell™ technology offers key advantages in skin repigmentation of burn scars, when combined with medical needling

Northridge, CA, Perth, Australia and Cambridge, United Kingdom — The combination of medical needling with a suspension of epithelial cells provided by ReNovaCell™ can restore pigment on burn scars, according to a randomised clinical trial from Germany published in Burns, the journal of the International Society for Burn Injuries, Avita Medical said today.

Read more »

Dimerix: Australian Research Council Linkage Grant to Progress Discovery Platform

MELBOURNE, Australia - Dimerix Limited (ASX: DXB), a clinical-stage biotechnology Company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced the Australian Research Council (ARC) had awarded a AUD$499,000 Linkage Grant to a consortium that includes Dimerix working with the Harry Perkins Institute of Medical Research and The University of Western Australia (UWA).

Read more »

Avita Medical: Research Confirms that ReCell® Reduces Long-Term Scarring and Itching Outcomes in Pediatric Burns Treatment

Northridge, CA and Cambridge, United Kingdom – The ReCell® Autologous Cell Harvesting Device effectively reduces the occurrence of long-term scarring and itching symptoms associated with pediatric burn treatment, compared to various treatment modalities, according to results from a UK study presented at a major burns conference this week.

Read more »

Seventure Partners Life Sciences Business Update 2016

Paris, France - Seventure Partners (‘Seventure’), one of Europe’s leaders in financing innovation, is pleased to provide a business update for the first four months of 2016.

Recent appointments and a number of positive milestones, both financial and in partnering collaborations from its portfolio, have meant a strong start to the year for Seventure, leading the way into a successful Q2 2016.

Read more »

Clinigen develops new Foscavir® (foscarnet sodium) product presentation

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has developed with Medisol and acquired from them the exclusive global rights to a 250ml bag form of foscarnet sodium, to continue the revitalisation of Foscavir®, in line with Group strategy.

Read more »

Regenerative Medicine Approach delivers healing and cost savings for Chronic Wounds

• Early intervention key for optimum treatment of chronic wound patients
• ReGenerCell™ healing of diabetic foot ulcers described as ‘remarkable’
• Combined treatment has potential to considerably reduce woundcare costs

Read more »

Avita Medical’s ReCell® Technology Demonstrated at Vitiligo Conferences in China

• More than 300 Chinese clinicians witness live demonstration of ReCell® technology
• Borun Group anticipates making ReCell® ‘routine’ treatment at its 23 hospitals
• China is home to an estimated 12 million vitiligo patients

Read more »

Nanobiotix: 2015 Annual Results

Paris, Cambridge – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015.

Read more »

Dimerix requests US FDA pre IND meeting and converts performance shares

MELBOURNE, Australia - Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced that it has filed a request to the US Food and Drug Administration (FDA) for a pre Investigational New Drug (IND) application meeting in relation to the Development Plan for DMX-200 in Focal Segmental Glomerularsclerosis (FSGS). This event triggers conversion of 75,000,040 Class B Performance Shares to ordinary shares.

Read more »

International Experts to Present on Avita Medical’s Regenerative Medicine Approach at Medical Symposium, London

Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Ltd. (ASX: AVH), (OTCQX:  AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, today announced that Mr Paul Hayes, Vascular Surgeon at Addenbrooke’s Hospital, UK and Mr Harvey Chant, Vascular Surgeon, The Royal Cornwall Hospital, UK will present on their experience and data on the use of Avita’s ReGenerCell™ in wound care at the Charing Cross International Symposium at Olympia Grand, London, UK from 26-29 April.  This year’s programme will focus on the challenges in the vascular and endovascular field.

Read more »

International Experts Honoured with Awards at 4th Annual Skin Regeneration Symposium

Cambridge, United Kingdom — Surgeons who treated scores of victims of an explosion in last year’s Taiwanese waterpark disaster, and a nurse deeply committed to treating  patients and researching venous leg ulcers (VLUs) have been honoured for their contributions to advancing Avita Medical’s regenerative medicine platform, the Company said today.

Read more »

ReNovaCell™ Skin Regeneration Technology Improves Pigmentation and Appearance of Scars

Cambridge, U.K. - Repigmentation and scar revision by using ReNovaCell™ can be significantly enhanced if used in conjunction with other mainstream cosmetic surgical techniques, according to an array of findings from leading aesthetic surgeons, Avita Medical said today.

Read more »

ReGenerCell™ Skin Regeneration Technology Decreases Size and Pain in Chronic Wounds

Cambridge, United Kingdom — Findings from top clinicians presented at the 4th Annual Skin Regeneration Symposium (SRS) at the University of Cambridge showed that ReGenerCell™, which uses Avita Medical’s proprietary technology, positively affects chronic wound size and associated pain whilst reducing the time required for wound healing.

Read more »

Dimerix Receives TGA Special Access Scheme Approval to Continue to Supply Propagermanium to Kidney Patients on its DMX-200 Phase II trial

Melbourne, Australia: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced that the Therapeutic Goods Administration in Australia (TGA) has confirmed that Dimerix can continue to supply propagermanium to participants in the DMX-200 clinical trial upon clinician approval and participant agreement.

Read more »

Skin Regeneration Technology Critical to Recovery and Quality of Life in Burns Patients Say Top Clinicians

Extensive Burns Research Data Presented at Skin Regeneration Symposium in Cambridge, UK

  • ReCell® technology improves burn wound healing, reduces scarring, discoloration and itching
  • ReCell® effective for extreme burns in emergency situations
  • 95% healing in less than 2 months achieved with ReCell® for explosion patient with 70% burn
  • Leading EU hospital incorporating ReCell® technology into general protocol in Burns Unit
Read more »

MINDACT Trial Findings on Agendia’s MammaPrint to be Presented during AACR Annual Meeting 2016

Irvine, CA, USA and Amsterdam, the Netherlands - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that results from the initial analysis of the primary objective of the EORTC 10041/ BIG 3-04 study “Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy” (MINDACT) will be presented at the AACR Annual Meeting 2016, April 16-20 in New Orleans, LA.

Read more »

AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon

San Diego, U.S. – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon. 

Read more »

Dr Richard Butt appointed CEO

Stevenage, UK - Apollo Therapeutics, (‘Apollo’), the investment fund focused on driving therapeutic innovation through university collaboration, has appointed Dr Richard Butt as CEO, effective from 23 May 2016. 

Read more »

AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

San Diego – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.

Read more »

Abcam enables faster drug and biomarker discovery with immunoassay research suite

Matched antibody pair kits provide assays with reproducible, sensitive and high-throughput detection

Read more »

GE Healthcare expands European capabilities to support accelerated biomanufacturing

• Large volume sterile liquid handling capacity doubled
• Rapid Response Production service for research, process development, and bioproduction launched

Read more »

Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe

Nijmegen, the Netherlands - Synthon today announced that it has successfully concluded the decentralized procedures for glatiramer acetate, a therapeutically equivalent version of the originator medicine Copaxone®* for the treatment of relapsing remitting multiple sclerosis (RRMS). All 29 member states included in the decentralized procedures supported approval of the product.

Read more »

Forbion closes third life sciences fund, FCF III, raising over $200m

Investment focus on European, US & Canadian private companies developing novel drugs, medical devices and diagnostics

Read more »

AdAlta Announces i-body Publication in the Journal of Biological Chemistry

Melbourne, Australia - AdAlta Limited, the drug discovery and development company, today announced the first publication of a scientific peer-reviewed paper describing the multiple potential applications of its i-body platform technology to address a number of major unmet medical needs.

Read more »

Seventure Partners Announces Key Appointments to Strengthen its Microbiome and Food-Health Expertise

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, today announced that it has furthered strengthened its Life Sciences team with two new appointments; Professor Denise Kelly joins as an Investment Advisor whilst Oxana Kukhaneva has been appointed Venture Partner.

Read more »

AmpliPhi Biosciences Announces Conversion of all Series B Redeemable Preferred Stock into Common Stock

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that all 7.5 million shares of its outstanding Series B convertible preferred stock have been converted into common stock following the receipt of elections by more than two-thirds of the preferred stock holders in accordance with AmpliPhi’s articles of incorporation.

Read more »

Imperial Innovations: Strategic relationships developed and additional funds raised

London, UK - Imperial Innovations Group plc (AIM: IVO, “Innovations” or “the Group”), a leading technology commercialisation and investment group, has published its results for the six months ended 31 January 2016.

Read more »

Abzena and FairJourney Biologics form alliance to provide continuum of antibody services from discovery to manufacture

Cambridge, UK and Porto, Portugal – Abzena plc (AIM: ABZA, ‘Abzena’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products and FairJourney Biologics (‘FJB’), a global antibody discovery and engineering company, provide further information on their marketing alliance.

Read more »

Avita Medical Announces 4th Annual Skin Regeneration Symposium

Northridge, CA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Ltd, (ASX: AVH), (OTCQX: AVMXY), a company specialising in treatments for wounds and skin defects, today announced that  some of the latest research in its field of regenerative medicine will be unveiled at a meeting being held at the University of Cambridge next week.

Read more »

AmpliPhi Biosciences Reports Full-Year 2015 Financial Results

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the fiscal year ended December 31, 2015.

Read more »

Clinigen joins two key European alliances in the fight to protect patients from the threat of counterfeit drugs

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, has become a full member of the European Alliance for Access to Safe Medicines (EAASM) and Alliance for Safe Online Pharmacy in the EU (ASOP EU), both aiming to protect patients from the dangers of falsified or counterfeit drugs.

Read more »

Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund

Geneva, Switzerland, and Ingelheim, Germany – Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines.

Read more »

GE Healthcare launches collaborative research scheme to support growth of Turkish biopharmaceutical industry

Call open for upstream and downstream bioprocess projects to be based at Bioprocessing Technology and Training Laboratory at GE’s Turkey Innovation Center in TeknoPark

Read more »

Mucosis to Present at World Vaccines Congress 2016

Groningen, the Netherlands – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, will present key data tomorrow at the 16th annual World Vaccines Congress US. The event is taking place from today until 31 March in Washington D.C., USA. This will be the 2nd year running that Mucosis has presented at the event.

Read more »

ITM and Scil Proteins Announce New Partnership for Targeted Radio Conjugates

Garching, Germany and Halle, Germany –  ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in affinity ligands and targeted carriers, today announced they have entered into a partnership covering the field of targeted radio conjugates.

Read more »

Adherium Establishes North American Operations and Appoints Senior Vice President of Business Development to Lead Market Expansion

Melbourne, Australia – Adherium Limited (ASX: ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, today announced the establishment of a new entity in the North American market, Adherium North America, Inc., based in San Francisco.  Adherium also announced the appointment of James Hattersley as Senior Vice President of Business Development, North America to lead market expansion.

Read more »

Strategic prioritisation on discovery platform and commercialisation

e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces its full year results for the year ended 31 January 2016.

Read more »

EP Vantage Releases its Annual Analysis of Pharma & Biotech and Medtech Sector Performance: 2015 in Review Reports

London, Boston, San Francisco, Tokyo – Funding for early stage biopharma and medtech research dwindled in 2015, as investors shifted their support to more mature companies. These findings and more were released today as part of the Pharma & Biotech 2015 in Review and Medtech 2015 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate Ltd.

Read more »

Innovations Portfolio Company TopiVert Reports Successful Phase I Clinical Study for the Treatment of Ulcerative Colitis

Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) is pleased to note that portfolio company TopiVert Pharma Ltd (“TopiVert” or the “Company”), has today announced positive Phase I study results for TOP1288, its lead compound for the treatment of ulcerative colitis (UC).

Read more »

Polyganics appoints Dr Jan Öhrström to Supervisory Board

Groningen, The Netherlands – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has appointed Dr Jan K. Öhrström to its Supervisory Board. The appointment is effective immediately.

Read more »

Adherium Confirms Clearance to Market in Canada for Flagship Products

Melbourne, Australia: Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that it has received final clearance to market in Canada for its SmartTurbo and SmartTouch devices. The SmartTurbo product works with AstraZeneca’s Symbicort® Turbuhaler, and the SmartTouch device with a range of pressurised metred dose inhalers supplied by a number of pharmaceutical companies, including GSK and Chiesi.

Read more »

Avita Medical Completes Repigmentation Study Enrollment

Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Ltd. (ASX: AVH), (OTCQX:  AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, today announced that it has enrolled its final patient in a study to evaluate the optimal deployment of ReNovaCellTM in patients with pigmentation defects.

Read more »

Nanobiotix completes a EUR 21.3 million private placement of new ordinary shares

Paris, Cambridge – NANOBIOTIX (the “Company”) (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the successful completion of a private placement of a total amount of approximately EUR 21.3 million.

Read more »

Avita Medical signs Distributor Deal with China’s largest healthcare Group

Northridge, CA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Ltd, (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects, has signed an exclusive distribution deal for China with the country’s leading healthcare group, Sinopharm.

Read more »

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – ADC Therapeutics (ADCT), the oncology drug development company, announces that the first patient has been dosed in a Phase I trial to evaluate its antibody drug conjugate (ADC) ADCT-402 in B-cell non-Hodgkin Lymphoma (B-NHL).

Read more »

Business update – strong second half momentum

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides the following update.

Read more »

Avita Medical Announces Positive Results from Randomized, Multicentre EU Study of ReGenerCell™ for Treatment of Chronic Venous Leg Ulcers

Northridge, CA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Ltd, (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects today reported positive results from the Company’s multicentre clinical trial of ReGenerCell™ in the treatment of chronic Venous Leg Ulcers (VLUs). In the seven-centre, 52-patient randomized study, ReGenerCell™ demonstrated statistically significant improvements in key measures of wound healing, pain and quality of life.

Read more »

Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings

Amsterdam and Irvine, CA – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that two poster presentations will be given at the 2016 European Breast Cancer Conference (EBCC), March 9-11 in Amsterdam, Netherlands. The studies looked at the use of the company’s MammaPrint 70-Gene Breast Cancer Recurrence assay in diagnostic testing as well as in large clinical studies, such as the MINDACT trial, the findings from which are expected to be presented later this year.

Read more »

AmpliPhi Biosciences CEO to Present at 28th Annual ROTH Conference

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi’s CEO, will present a corporate overview on Tuesday, March 15, 2016 at the 28th Annual ROTH Conference at the Ritz Carlton in Dana Point, California.
The presentation is scheduled to begin at 9:00 am Pacific Time. A live webcast of the presentation will be accessible on AmpliPhi’s website at http://ampliphibio.com/events-and-presentations.html. A replay will be available for 30 days following the presentation.

Read more »

Avita Medical Announces U.S. FDA Approval for Increase in Compassionate Use of ReCell® Patient Cases

Northridge, CA and Cambridge, United Kingdom – Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for a second expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®.

Read more »

CONTINUED STRONG GROWTH WITH EPS UP 21%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services company, has today published its half year results for the six months ended 31 December 2015.

Read more »

Clinigen acquires US-approved Totect® (dexrazoxane) from Biocodex to become the only global source for the treatment of anthracycline extravasation

London, UK - Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has acquired Totect® (dexrazoxane) from Biocodex USA, a product that is patent protected in US, Canada and Mexico.

Read more »

Avita Medical Launches Expanded Regenerative Product Range in Europe

• Enhanced commercial reach with expanded product range launched in Europe
• Range now includes three CE-marked products: ReGenerCell™ (chronic wounds), ReNovaCell™ (repigmentation) alongside ReCell® (burns)
• Products available through expanded European distributor network in UK, France, Germany, Austria and Switzerland as well as direct elsewhere

Read more »

Vortex BioSciences co-founder receives US Presidential award for groundbreaking “Liquid Biopsy” technique

London, UK - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group notes its operating subsidiary, Vortex Biosciences’ (‘Vortex’) announcement about its co-founder receiving the US Presidential Early Career Award for Scientists and Engineers (PECASE). The award is the highest honor bestowed by the United States government for accomplishments in science and engineering.

Read more »

Instinctif Partners takes agency top spot at PRCA City & Financial Awards

 

We are thrilled to announce that we have been named City and Financial Agency of the Year at the PRCA City and Financial Awards 2016.

For further information please click here

Read more »

DySIS Medical Signs Significant Deal with ITEM Medical Technologies to Support National Screening Programme in Turkey

DySIS Colposcope to be incorporated into national cervical screening programme

Read more »

New Understanding of the Mechanism of Neurodegeneration Leads to a Novel Approach to Treatment for Alzheimer’s Disease

• Peer-reviewed research validates theory that a novel peptide found at raised levels in Alzheimer’s disease brain is primary driver of neurodegeneration
• Innovative drug prototype shown to block its damaging activity in human cell lines suggests a promising strategy for future therapeutics

Read more »

Wanda™ partners with leading US Hospital Group Dignity Health™ to launch oncology decision support software platform - OncoVerse™

London, UK - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that its operating subsidiary, Wanda, has signed a collaborative deal with one of the US’s biggest hospital groups, Dignity Health, to launch OncoVerse, a digital health oncology care platform.

Read more »

On Rare Disease Day, Clinigen and CheckOrphan celebrate over 100

London, UK - Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, and CheckOrphan, the leading news and information source for rare diseases, announce the 128th addition to a unique online access program register for rare diseases1 on Rare Disease Day 2016, the first anniversary of its launch.

Read more »

Nanobiotix 2015 Q4 and annual revenues

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205) – a late clinical-stage Nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenues for Q4 and the annual revenues for the year ended December 31, 2015.

Read more »

Ablynx Announces 2015 Full Year Results

GHENT, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced its financial results for 2015, which have been prepared in accordance with IFRS as adopted by the European Union.

Read more »

Innovations leads £13.5m funding round in Precision Ocular Ltd

Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has led a £13.5 million investment round in Precision Ocular Ltd (Precision Ocular), a London-based retinal therapeutics company.

Read more »

Dimerix receives US Patent allowance for chronic kidney disease drug candidate

Melbourne, Australia: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced it had received a Notice of Allowance from the United States Patent and Trade Mark Office (USPTO) for its patent covering the use of DMX-200 in the treatment of kidney disease.

Read more »

NetScientific appoints Professor Stephen Smith as Non-Executive Director

London, UK - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints Professor Stephen Smith as Non-Executive Director, with effect from today. Professor Smith will also join both the audit and remuneration committees.

Read more »

Forbion invests in Akarna Therapeutics $15 Million Series B Financing to Develop Novel FXR Agonist-Based Therapies for the Treatment of NASH and other Fibrotic Diseases

Funding to advance Akarna’s lead drug candidate through human proof-of-concept studies

Read more »

Avita Medical Appoints Distributor for Germany, Switzerland, Austria

Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, today announced that it has appointed a distributor to sell its devices into the German, Austrian and Swiss markets.

Read more »

New England Journal of Medicine Publishes Ablynx’s Phase II TITAN Study

Ghent, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that the results of the Company’s worldwide Phase II TITAN study1 with caplacizumab for patients with acquired thrombotic thrombocytopenic purpura (aTTP) have been published in today’s issue of the New England Journal of Medicine (NEJM).

Read more »

AmpliPhi Biosciences Announces Award of Federal Research Grant from Australia to its Collaboration Partner, Westmead Institute

Funds intended to develop new bacteriophage therapeutics for serious infections caused by E. Coli and Klebsiella

Read more »

PDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies

London, UK - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed a Cooperative Research and Development Agreement with the National Cancer Institute, a division of the US National Institutes of Health. The goal is to co-develop novel cancer immunotherapies through Phase II clinical trials that will start in 2016 and 2017.

Read more »

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 in Acute Myeloid Leukemia

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – ADC Therapeutics SA (ADCT), the oncology drug development company, announces that the first patient has been dosed in a Phase I trial to evaluate its lead antibody drug conjugate (ADC) ADCT-301 in Acute Myeloid Leukemia (AML).

Read more »

Crescendo Biologics Presents Key Oncology Data on Humabody™ Drug Conjugates

Cambridge, UK – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced a major breakthrough in its Humabody™ Drug Conjugate (HDC) programme.

Read more »

Innovations leads £5m Series A round in encapsulation specialist Aqdot

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has led a £5.0 million Series A funding round in portfolio company Aqdot Limited (‘Aqdot’ or the ‘Company’) the Cambridge (UK) based specialist chemical company.

Read more »

Imperial Innovations: Placing to raise £100 million

London, UK - Imperial Innovations Group plc (AIM: IVO, “Innovations”, the “Company”, the “Group”) announces that it is proposing to conditionally raise £100 million (before expenses) by way of a placing with clawback at 425p per new Ordinary Share (the “Placing”). Innovations believes that there are significant opportunities available to the Group to invest in existing and new portfolio companies across its target investment areas, and to seek to further accelerate its growth and to enhance returns to shareholders.

Read more »

Premaitha Health partners with Visional Medical to provide the IONA test to pregnant women in India

Manchester, UK and Chennai, India – Premaitha Health plc (AIM: NIPT, “Premaitha” or “the Company”) developer of the IONA® test, the first CE-marked non-invasive prenatal screening (NIPT) product, has signed an agreement with Visional Medical to provide access to the benefits of NIPT for pregnant women in India. Visional Medical is a new organisation based in the UK and India that aims to deliver better diagnostic tests to the developing world.

Read more »

Premaitha Health partners with Leeds Teaching Hospitals NHS Trust to offer pregnant women safer non-invasive prenatal screening service

Manchester and Leeds, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal screening (NIPT) product has partnered with Leeds Teaching Hospitals NHS Trust to provide a private NIPT screening service for pregnant women in the region.

Read more »

Innovations portfolio company MISSION Therapeutics raises £60 million to progress innovative drug platform

Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) announces that portfolio company MISSION Therapeutics (‘MISSION’ or ‘the Company’) has raised £60.0 million to advance a series of first-in-class small molecule drugs candidates from its innovative drug platform.

Read more »

Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property

Cambridge, UK - Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the appointment of Dr Barbara Fleck as Head of Intellectual Property.

Read more »

Ablynx to Receive €8 Million Milestone as Boehringer Ingelheim Starts First Patient Study with a Bi-Specific Nanobody in Oncology

Ghent, Belgium - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the study is to evaluate the safety profile and dosing schedule for this Nanobody.

Read more »

At the forefront of health innovation

Our core strength is supporting organisations at the interface of innovation and wealth creation – to help them communicate their innovative science and new medical devices and treatments. With any new technologies, communications is a critical tool to ensure the innovations are adopted by customers and accepted and appreciated by the wider publics and society. In a sector that burns billions in cash ahead of any new product launch, it’s also vital that investors are excited by the potential and can see the value in new innovations. It’s truly an honour to be able to work with so many entrepreneurs and game-changing companies, in areas such as stem cells, gene therapy, immune-oncology, personalised medicine, the microbiome and genetic-based diagnostics. Whilst the individual brands of many of our early-stage clients are not widely known, they are changing the health outlook for all of us, and it’s exciting to be part of it. Read more

Read more »

PacificGMP makes two senior appointments

Cambridge, UK – Abzena plc (AIM:ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, announces that its US biomanufacturing subsidiary, PacificGMP, has made two senior appointments to support its growth.

Read more »

Vascular Flow Technologies closes £10M financing round for strategic realignment

Dundee, UK – Vascular Flow Technologies (VFT), the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announced that it has closed a £10 million financing round. The funds will support VFT’s realignment of business strategy to focus on research and development, as well as the strategic joint development and out-licensing agreements with leading industry partners.

Read more »

Premaitha Health signs two new customers for its clinical laboratory NIPT screening service

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal screening (NIPT) product has signed two new service contracts with customers in Armenia and Republic of Moldova. These contracts expand Premaitha’s customer base into new international markets, enabling more pregnant women to benefit from the safety and accuracy of NIPT.

Read more »

Polyganics Receives FDA 510(k) Clearance for Nerve Capping Device NEUROCAP

Groningen, The Netherlands – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has received FDA 510(k) clearance for NEUROCAP, an innovative device designed to reduce painful neuroma formation and thereby facilitate tissue repair and regeneration.

Read more »

Innovations genomics company Inivata completes £31.5m Series A funding round

Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) announces that portfolio company Inivata Limited (‘Inivata’ or the ‘Company’) has completed a £31.5 million Series A fundraising.

Read more »

Board Change

London, UK - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced the resignation from the board of Peter Thoms, Chief Financial Officer. Peter leaves the company in order to pursue new challenges, particularly in the technology sector. Peter has been with the Group since inception and has been heavily involved in building the current business. His contribution has been significant and much appreciated. The Board wish Peter all the best in his new ventures.

Read more »

Significant licence deal for ThioBridge™ ADC linker technology signed with US biotech partner

Cambridge, UK – Abzena plc (AIM:ABZA), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, has signed a significant licensing deal for its novel site specific ThioBridge™ antibody drug conjugate (ADC) linker technology. The partner is a publicly listed US biotech company that is developing and commercialising oncology therapies, including ADCs.

Read more »

Instinctif Partners announces record Healthcare sector client wins in 2015

Instinctif Partners’ Life Sciences team provides consultancy to over 50 global pharma, healthcare and biotech companies

Read more »

Innovations joins consortium of three world-leading UK universities and three global pharmaceutical companies to launch £40m therapeutics fund

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has committed £3.3m to the new £40 million Apollo Therapeutics Fund (‘Apollo’ or the ‘Fund’) launched today.

Read more »

Consortium of world-leading UK universities and global pharmaceutical companies launch £40 million fund to drive therapeutic innovation

  • Unique collaboration between AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, UCL (University College London) and the University of Cambridge, to drive forward therapeutic innovation
  • £40 million Apollo Therapeutics Fund aims to significantly improve the speed and potential of university research being translated into novel medicines
  • First time global pharmaceutical companies and world-leading universities* have created this type of fund
Read more »

Polyganics and MicroAire sign exclusive distribution agreement for peripheral nerve repair portfolio in the US, Canada and Puerto Rico

Groningen, The Netherlands – Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve repair, neurosurgery, general surgery, as well as ear, nose & throat surgery, today announced it has signed an exclusive distribution agreement with its strategic partner MicroAire Surgical Instruments LLC for the company’s entire peripheral nerve repair (PNR) portfolio in the US, Canada and Puerto Rico.

Read more »

AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01

San Diego, CA – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.

Read more »

Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London

Groningen, the Netherlands – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, today announced that it has secured a €3.7 million (£2.77 million) translational fund award from the Wellcome Trust to progress its proprietary intranasal Respiratory Syncytial Virus (RSV) vaccine, SynGEM®, into phase I and IIa human clinical trials. The trials will be led by world-leading expert in RSV and member of Mucosis’s Scientific Advisory Board, Professor Peter Openshaw FRCP FMedSci and Dr. Christopher Chiu of the National Heart & Lung Institute, Imperial College London.

Read more »

AmpliPhi Biosciences Announces Appointment of Steve R. Martin as Chief Financial Officer

San Diego, CA, USA – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Steve R. Martin has been appointed as its new Chief Financial Officer. He will be based in AmpliPhi’s San Diego office.

Read more »

Half year trading update

Solid H1 performance, integration of recent acquisitions on track and well positioned for good H2

Read more »

Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders

Cambridge, UK – Abzena plc (AIM:ABZA), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that a grant for €1.9 million has been awarded under the Eurostars™ programme to a consortium that comprises its subsidiary, Antitope Limited, Dutch biopharmaceutical companies Prothix BV and Aristi Biotech BV, the University Medical Center Utrecht (UMCU, the Netherlands) and GenOway, a French company.

Read more »

Innovations invests £25m in new £50m UCL Technology Fund to increase deal flow and strengthen relationship with UCL

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has committed £24.75 million to the new UCL Technology Fund (‘the Fund’) launched today.  This is the first investment fund that UCL (University College London) has established to commercialise its multidisciplinary research.

Read more »

Premaitha Health welcomes recommendation for NHS provision of non-invasive prenatal testing

Manchester, UK – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal screening (NIPT) product, welcomes the UK National Screening Committee’s (NSC) recommendation to routinely offer NIPT testing on the NHS to high risk pregnant women as part of the standard fetal anomaly screening programme.

Read more »

Avita Medical Appoints Distributors in Japan and South Korea

Northridge, CA, Perth, Australia and Cambridge, United Kingdom – Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects, announced today that it has signed distribution agreements for Japan and South Korea for its ReCell® device.

Read more »

GE Healthcare, FedDev Ontario commit CAD $40M for new CCRM-led centre to solve cell therapy manufacturing challenges

Chalfont St. Giles, UK and Toronto, Canada – GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies in Toronto with an investment of CAD $40M from GE and FedDev Ontario. The centre is being established to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. CCRM and GE will welcome partners from pharma, biotech and cell therapy companies to bring this initiative to life.

Read more »

Avita Medical Transforms Board with Three New Appointments

Northridge, CA, Cambridge, United Kingdom, Perth, Australia – Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects, has transformed its Board of Directors with three new key appointments that significantly strengthen the Company’s commercialisation experience. The new appointments, effective today, will be instrumental in guiding the Company’s US launch plans for its lead regenerative medicine product, ReCell®.

Read more »

TROD Medical receives CE Mark Approval for Encage™

Leuven, Belgium - TROD Medical NV, the medical device company developing tools for focal ablation, today announced that it has received CE Mark Approval for its Encage™ device.
 

Read more »

Avita Medical Completes Patient Recruitment for its FDA Approval Study Evaluating Use of ReCell® in Acute Burns

Northridge, CA, USA and Cambridge, United Kingdom — Avita Medical Ltd. (ASX: AVH), (OTCQX:  AVMXY), a regenerative medicine Company specializing in the treatment of wounds and skin defects, today announced that patient recruitment is complete for its U.S. Food and Drug Administration (FDA) approval study evaluating the use of ReCell® in combination with meshed autografting for the treatment of partial-thickness and full-thickness acute burns.

Read more »

AmpliPhi Acquires Key Bacteriophage Assets from UK-based Novolytics

San Diego, CA, Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has acquired key assets from UK-based Novolytics Ltd., including bacteriophage-related intellectual property, bacteriophage libraries, formulation and regulatory know-how as well as GLP toxicology data.

Read more »

Instinctif Partners’ Clients Presenting in San Francisco at the 34th JP Morgan Healthcare Conference and EBD Biotech Showcase 2016

London: Instinctif Partners, the business communications consultancy, will be in attendance at the forthcoming life sciences conferences in San Francisco supporting its presenting and attending clients.

Read more »

Ablynx to present at the 34th Annual J.P. Morgan Healthcare Conference

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday 14 January 2016 at 10:30 a.m. Pacific Standard Time (07:30 p.m. Central Eastern Time).

Read more »

Adherium to Present Corporate Overview at Biotech Showcase 2016

Melbourne, Australia: Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease, will present a corporate overview at the EBD Biotech Showcase Conference, taking place in San Francisco between 11-13 January 2016.

Read more »

Clinical Network Services (CNS) Expands its BioDesk Service into Washington D.C.

Brisbane, Australia - Clinical Network Services (CNS), an integrated service group focused on clinical product development and headquartered in Australia with offices in New Zealand, the UK and the USA, has announced that it has established a new office on the East coast of the USA for its expanded BioDesk division.

Read more »

NetScientific portfolio company, Glycotest Inc., appoints world leading medical advisory board chaired by David Chernoff, M.D.

London, UK – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints a medical advisory board of leading liver experts to advise on the development of Glycotest’s diagnostic tests for liver related diseases.

Read more »

Appointment of Non-Executive Chairman

e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce the appointment of Iain Ross to the Board of Directors as Non-Executive Chairman.

Read more »

Wishing you a successful 2016

‘Dining with the Diplodocus’: looking forward to the annual BIA dinner in the wonderful setting of the Natural History Museum, London, 28 January.

Sue Charles, Dr Lynne Trowbridge and Melanie Toyne Sewell look forward to seeing you there.

 

Read more »

Premaitha Health launches Workflow Manager system for the IONA® test to support clinical laboratory customers

Comprehensive clinical sample and patient data tracking from receipt to result

Read more »

Nanobiotix starts a new research program, in Immuno Oncology, with its lead product NBTXR3

Paris, Cambridge – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology.

Read more »

FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer

Paris France, Cambridge MA, USA – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the US Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application on the 30th of December. This allows Nanobiotix to launch its first clinical study in the US for its lead product NBTXR3 in prostate cancer, a new and very significant indication.

Read more »